Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: GlobeNewswire
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced the closing of its previously announced underwritten public offering of 7,475,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 975,000 additional shares, at a public offering price per share of $62.00. The gross proceeds to Spyre from the offering were approximately $463.5 million before deducting underwriting discounts and commissions and other offering expenses payable by Spyre. Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC acted as the joint book-running managers for the offering. LifeSci Capital LLC acted as passive bookrunner for the offering. A registration s
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (SYRE) had its price target raised by JonesTrading from $64.00 to $95.00. They now have a "buy" rating on the stock.MarketBeat
- Spyre Therapeutics (SYRE) Is Up 32.7% After $403 Million Equity Raise On Positive Phase 2 Data [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal [Seeking Alpha]Seeking Alpha
- Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common StockGlobeNewswire
- Spyre Therapeutics (SYRE) had its price target raised by Robert W. Baird from $65.00 to $90.00. They now have an "outperform" rating on the stock.MarketBeat
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 4/16/26 - Form 8-K
- 4/16/26 - Form 424B5
- 4/13/26 - Form 424B5
- SYRE's page on the SEC website